العلاج من الخط الأول لسرطان الخلايا الكبدية المتقدم (مرحلة BCLC-C) في تليف الكبد Child-Turcotte-Pugh A

References

DOI: 10.1097/HEP.0000000000000466

• Systemic therapy should be offered to patients with preserved liver function (Child-Turcotte-Pugh A or well-selected Child-Turcotte-Pugh B cirrhosis), ECOG PS 0-1, who have BCLC Stage C HCC, or BCLC Stage B HCC not amenable to or progressing after locoregional therapy (Level 1, Strong Recommendation).
• Patients with advanced HCC who have Child-Turcotte-Pugh A cirrhosis should be offered atezolizumab plus bevacizumab or durvalumab plus tremelimumab as preferred first-line therapy options (Level 2, Strong Recommendation).
• Patients considered for atezolizumab plus bevacizumab should undergo an EGD to assess for high-risk stigmata of variceal or other GI bleeding (Level 5, Strong Recommendation).